Efficacy of a novel 3-hydroxypyridine derivative in the stabilization of free radical oxidation in post-traumatic osteoarthritis: A randomized preclinical study
Open Access
- 28 August 2026
- journal article
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 33 (4) , 45-57
Abstract
Background. While diverse conservative options exist, the prevalence of post-traumatic osteoarthritis remains high. This fact necessitates the search for novel multitarget pathogenetic agents to prevent disease progression and irreversible joint tissue degeneration resulting from delayed treatment. Objective. To evaluate the effect of a novel 3-hydroxypyridine derivative (2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate) on free radical oxidation and antioxidant status in an experimental model of post-traumatic osteoarthritis. Methods. A randomized preclinical study was conducted on 55 outbred white male rats weighing 190–220 g. The rats were divided into five groups: intact animals (Group 1; n = 15) and four groups with induced knee joint injury (Groups 2–5; n = 10 each). Group 2 remained untreated, while Groups 3, 4, and 5 received pharmacotherapy with ibuprofen (6.35 mg/kg), ethylmethylhydroxypyridine succinate (45.58 mg/kg), and 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate (11.65 mg/kg), respectively. Free radical oxidation and antioxidant status were evaluated in plasma and erythrocytes based on biochemiluminescence data, concentrations of primary and secondary lipid peroxidation products, and antioxidant enzyme activity. Statistical analysis of the obtained data was conducted via one-way analysis of variance followed by Tukey’s post hoc test. Calculations were performed using the SPSS Statistics 20.0 software (IBM, USA). Differences were considered statistically significant at p < 0.05. Results. The compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate demonstrated the highest efficacy compared to both ethylmethylhydroxypyridine succinate and ibuprofen. The pronounced antioxidant effect of this novel 3-hydroxypyridine derivative was characterized by the stabilization of free radical oxidation by the end of the experiment, with the evaluated parameters approaching reference values. Specifically, compared to the ibuprofen-treated group, the conjugated diene level was 45% lower ( p 2 < 0.001). Similarly, in plasma and erythrocyte samples undergoing spontaneous oxidation, malondialdehyde levels were lower by 35% and 24%, respectively ( p 2 < 0.001). The conjugated diene level in the ethylmethylhydroxypyridine succinate group exceeded that of the novel compound group by 20% ( p 3 < 0.001), while plasma and erythrocyte malondialdehyde levels were higher by 7% ( p 3 = 0.048) and 9% ( p 3 = 0.041), respectively. Furthermore, an increased antioxidant activity was observed in Group 5. The plasma superoxide dismutase activity was 86% greater than in the ibuprofen-treated group ( p 2 < 0.001) and surpassed the group treated with ethylmethylhydroxypyridine succinate by 37% ( p 3 < 0.001). The total chemiluminescence produced was 32% higher than in the ibuprofen-treated group ( p 2 < 0.001) and 12% greater than in the ethylmethylhydroxypyridine succinate group ( p 3 = 0.028), indicating an enhanced antioxidant potential. Conclusion. The novel compound 2-ethyl-6-methyl-3-hydroxypyridinium 4-isobutylphenylpropanoate effectively inhibits lipid peroxidation and restores antioxidant enzyme activity. Its administration mitigates free-radical damage to joint tissues and accelerates the restoration of antioxidant potential, both by enhancing the activity of key enzymes and directly lowering free-radical levels. These findings indicate its high predicted efficacy as a pathogenetic agent in the comprehensive management of post-traumatic osteoarthritis.Keywords
This publication has 25 references indexed in Scilit:
- Clinical and omics biomarkers in osteoarthritis diagnosis and treatmentJournal of Orthopaedic Translation, 2025
- Current status of catabolic, anabolic and inflammatory biomarkers associated with structural and symptomatic changes in the chronic phase of post-traumatic knee osteoarthritis– a systematic reviewOsteoarthritis and Cartilage Open, 2023
- Post-traumatic osteoarthritis: A review of pathogenic mechanisms and novel targets for mitigationBone Reports, 2023
- Assessing post-traumatic changes in cartilage using T1 dispersion parametersMagnetic Resonance Imaging, 2023
- Cyclic loading regime considered beneficial does not protect injured and interleukin-1-inflamed cartilage from post-traumatic osteoarthritisJournal of Biomechanics, 2022
- Independent changes in bone mineralized and marrow soft tissues following acute knee injury require dual-energy or high-resolution computed tomography for accurate assessment of bone mineral density and stiffnessJournal of the Mechanical Behavior of Biomedical Materials, 2022
- Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic OsteoarthritisACS Nano, 2021
- Prevention of posttraumatic osteoarthritis at the time of injury: Where are we now, and where are we going?Journal of Orthopaedic Research, 2021
- Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United StatesOsteoarthritis and Cartilage, 2019
- Acute Changes in NADPH Oxidase 4 in Early Post‐Traumatic OsteoarthritisJournal of Orthopaedic Research, 2019